All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
The lym Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the lym Hub cannot guarantee the accuracy of translated content. The lym and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View lymphoma & CLL content recommended for you
Can CD30 CAR T-cell consolidation improve outcomes after ASCT for patients with CD30+ lymphomas?
Featured:
Marcie RichesDuring the 2021 TCT Meetings Digital Experience, the Lymphoma Hub spoke to Marcie Riches, UNC-Chapel Hill, Chapel Hill, US. We asked, Can CD30 CAR T-cell consolidation improve outcomes after ASCT for patients with CD30+ lymphomas?
Can CD30 CAR T-cell consolidation improve outcomes after ASCT for patients with CD30+ lymphomas?
In this video, Riches discusses efficacy and safety results from a phase I dose-finding trial evaluating the use of CD30+ CAR T cells as consolidation therapy following autologous stem cell transplantation (ASCT). These results include 1-year progression-free survival and tolerability in patients with Hodgkin or T-cell lymphoma. She concludes by outlining future phase II trials for this CAR T-cell therapy.